This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dizon, D. S. Articles by Spriggs, D. R. Search for Related Content PubMed PubMed Citation Articles by Dizon, D. S. Articles by Spriggs, D. R.

Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer

From the Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to David Spriggs, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: spriggsd{at}mskcc.org

PURPOSE: The majority of patients with epithelial ovarian cancer (EOC) who achieve a complete remission with front-line chemotherapy develop recurrent disease. Carboplatin and paclitaxel are used for patients with platinum-sensitive recurrent disease, although there is little information regarding the response and survival in unselected patients treated with this strategy. We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC.

PATIENTS AND METHODS: Eighty-nine patients were identified who had a complete response to front-line platinum-based chemotherapy for EOC, relapsed 6 months after completion of front-line chemotherapy, and were treated with carboplatin and paclitaxel as second-line therapy.

RESULTS: Eighty-four cases were available for analysis of survival end points, and 66 were assessable for response. The median follow-up was 27 months. The overall response rate was 70%. The median progression-free interval for the cohort was 13 months (95% confidence interval [CI], 10.7 to 13.8 months). The 3-year survival rate was 72% (95% CI, 59.4 to 86.1%). Toxicity was limited, and no deaths from treatment were observed. Using this data, it is possible to construct a disease states model of EOC, which provides risk estimates for transitions between clinically distinct categories.

CONCLUSION: Re-treatment with carboplatin and paclitaxel is effective as initial therapy in recurrent EOC. This should form the basis of a randomized trial to determine the best agents for initial treatment of relapse from EOC in potentially platinum-sensitive patients.

This article has been cited by other articles:

				G Ferrandina, M Ludovisi, R De Vincenzo, V Salutari, D Lorusso, M Colangelo, T Prantera, M. Valerio, and G Scambia Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study Ann. Onc., August 1, 2007; 18(8): 1348 - 1353. [Abstract] [Full Text] [PDF]

				E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Onc., April 1, 2007; 18(4): 716 - 721. [Abstract] [Full Text] [PDF]

				P. Sabbatini, J. Dupont, C. Aghajanian, F. Derosa, E. Poynor, S. Anderson, M. Hensley, P. Livingston, A. Iasonos, D. Spriggs, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res., September 15, 2006; 12(18): 5503 - 5510. [Abstract] [Full Text] [PDF]

				P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]

				T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]

				A. J. Gonzalez-Martin, E. Calvo, I. Bover, M. J. Rubio, A. Arcusa, A. Casado, B. Ojeda, C. Balana, E. Martinez, A. Herrero, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study Ann. Onc., May 1, 2005; 16(5): 749 - 755. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design J. Clin. Oncol., August 1, 2004; 22(15): 3120 - 3125. [Abstract] [Full Text] [PDF]

				M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity J. Clin. Oncol., December 15, 2003; 21(24): 4611 - 4614. [Abstract] [Full Text] [PDF]

				R. F. Ozols Recurrent Ovarian Cancer: Evidence-Based Treatment J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163. [Full Text] [PDF]